(S)-环氧乙烷-2-羧酸钾 | 82079-45-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 中文名称: (S)-环氧乙烷-2-羧酸钾
• 英文名称: potassium (S)-oxirane-2-carboxylate
• 英文别名: potassium (S)-(-)-2,3-epoxypropanoate；potassium;(2S)-oxirane-2-carboxylate
• CAS: 82079-45-6
• 化学式: C₃H₃O₃*K
• 分子量: 126.153
• InChiKey: CMQCDPNYSJUSEH-DKWTVANSSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -4.86
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 包装等级：
  III
• 危险类别：
  4.1
• 危险性防范说明：
  P210,P240,P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P370+P378,P403+P233,P501
• 危险品运输编号：
  1325
• 危险性描述：
  H228,H315,H317,H319,H335
• 储存条件：
  -20°C，惰性气体

反应信息

• 作为反应物：
  描述：

  (S)-环氧乙烷-2-羧酸钾 生成 乙基 (2S)-2,3-环氧树脂丙烷酸酯
  参考文献：
  名称：

  LARCHEVEQUE, MARC;PETIT, YVES, BULL. SOC. CHIM. FR.,(1989) N, C. 130-139

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-丝氨酸 在 亚硝酸 、 potassium bromide 、 potassium hydroxide 作用下， 以 水 、 乙醇 为溶剂， 生成 (S)-环氧乙烷-2-羧酸钾
  参考文献：
  名称：

  Potent Inhibitors of a Shikimate Pathway Enzyme from Mycobacterium tuberculosis

  摘要：

  Tuberculosis remains a serious global health threat, with the emergence of multidrug-resistant strains highlighting the urgent need for novel antituberculosis drugs. The enzyme 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) catalyzes the first step of the shikimate pathway for the biosynthesis of aromatic compounds. This pathway has been shown to be essential in Mycobacterium tuberculosis, the pathogen responsible for tuberculosis. DAH7PS catalyzes a condensation reaction between P-enolpyruvate and erythrose 4-phosphate to give 3-deoxy-D-arabino-heptulosonate 7-phosphate. The enzyme reaction mechanism is proposed to include a tetrahedral intermediate, which is formed by attack of an active site water on the central carbon of P-enolpyruvate during the course of the reaction. Molecular modeling of this intermediate into the active site reported in this study shows a configurational preference consistent with water attack from the re face of P-enolpyruvate. Based on this model, we designed and synthesized an inhibitor of DAH7PS that mimics this reaction intermediate. Both enantiomers of this intermediate mimic were potent inhibitors of M. tuberculosis DAH7PS, with inhibitory constants in the nanomolar range. The crystal structure of the DAH7PS-inhibitor complex was solved to 2.35 angstrom. Both the position of the inhibitor and the conformational changes of active site residues observed in this structure correspond closely to the predictions from the intermediate modeling. This structure also identifies a water molecule that is located in the appropriate position to attack the re face of P-enolpyruvate during the course of the reaction, allowing the catalytic mechanism for this enzyme to be clearly defined.

  DOI：

  10.1074/jbc.m110.211649

文献信息

• 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
  申请人：安润医药科技（苏州）有限公司

  公开号：CN106146511A

  公开（公告）日：2016-11-23

  本发明公开了吡唑并嘧啶衍生物、制备方法、药物组合物及用途。本发明提供了一种如式I所示的吡唑并嘧啶衍生物，其立体异构体、溶剂合物、药学上可接受的盐、活性代谢产物或前体药物。本发明的如式I所示的吡唑并嘧啶衍生物对布鲁顿酪氨酸激酶(Btk)具有良好的抑制活性，尤其对肿瘤细胞的生长具有良好的体内体外抑制活性，有良好的市场化前景。
• Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
  申请人：G. D. Searle & Company

  公开号：US06362183B1

  公开（公告）日：2002-03-26

  An aromatic sulfonyl alpha-hydroxy hydroxamic acid compound that, inter alia, inhibits matrix metalloprotease activity is disclosed, as is a treatment process that comprises administering a contemplated aromatic sulfonyl alpha-hydroxy hydroxamic acid compound in an MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

  本文披露了一种具有芳香基的磺酰基α-羟基羟肟酸化合物，该化合物等方面抑制基质金属蛋白酶活性，以及一种治疗过程，包括向患有与病理性基质金属蛋白酶活性相关病症的宿主施用考虑中的芳香基磺酰基α-羟基羟肟酸化合物，其剂量有效地抑制MMP酶活性。
• [EN] PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIDOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE KRAS G12C ET DE KRAS G12D DANS LE TRAITEMENT DU CANCER
  申请人：AMGEN INC

  公开号：WO2021081212A1

  公开（公告）日：2021-04-29

  Provided herein are KRAS G12C and KRAS G12D inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了KRAS G12C和KRAS G12D抑制剂，其组成，以及使用这些抑制剂的方法。这些抑制剂对治疗多种疾病有用，包括胰腺癌、结直肠癌和肺癌。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。
• [EN] HETEROCYCLIC AMIDE DERIVATIVES WHICH POSSESS GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY<br/>[FR] DERIVES AMIDES HETEROCYCLIQUES POSSEDANT UNE ACTIVITE INHIBITRICE DE GLYCOGENE PHOSPHORYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2005018637A1

  公开（公告）日：2005-03-03

  A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example: R4 and R5 together are either -S-C(R6=C(R7)- or -C(R7)=C(R6)-S- ; R6 and R7 are independently selected from hydrogen and halo; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is halo, cyano or carboxy; R2 is for example methyl; R3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.

  该化合物的分子式为（1）或其药用可接受的盐或前药；（1）其中，例如：R4和R5一起是-S-C(R6=C(R7)-或-C(R7)=C(R6)-S-；R6和R7分别选择自氢和卤素；A是苯基或杂环芳基；n为0、1或2；R1为卤素、氰基或羧基；R2为例如甲基；R3为例如选择自卤(1-4C)烷基、二卤(1-4C)烷基、三氟甲基、羟基(1-4C)烷基、二羟基(2-4C)烷基、三羟基(3-4C)烷基、氰基(1-4C)烷基（在烷基上可选择性地取代羟基）、（1-4C)烷氧基(1-4C)烷基、（1-4C)烷氧基(1-4C)烷氧基(1-4C)烷基、二[(1-4C)烷氧](1-4C)烷基、(羟基)[(1-4C)烷氧](1-4C)烷基；具有糖原磷酸化酶抑制活性，因此在治疗与糖原磷酸化酶活性增加相关的疾病状态中具有价值。描述了制备化合物和含有它们的药物组合物的方法。